[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640080":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":63,"collaborators":65,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":20,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":51,"whyStopped":20,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Oregon Health and Science University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CMI","EXPERIMENTAL","Switching from mavacamten on day 1 to aficamten starting at week 2.",[13],"Drug: Aficamten",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Aficamten","Patients will be switched from mavacamten to aficamten. Mavacamten will be stopped at enrollment, and aficamten started 2 weeks later.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ahmad Masri","CONTACT","503-494-7551","masria@ohsu.edu",[28,49],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"St. Luke's Hospital - Mid America Heart Institute","NOT_YET_RECRUITING","Kansas City","Missouri","64111","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-94.57857,39.09973,{"lat":40,"lon":39},[43,47],{"name":44,"role":24,"phone":45,"phoneExt":20,"email":46},"Michael Nassif, MD","816-932-3458","mnassif@saint-lukes.org",{"name":44,"role":48,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":34,"countryCode":35,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Oregon Health & Science University","RECRUITING","Portland","Oregon","97239",{"type":37,"coordinates":56},[57,58],-122.67621,45.52345,{"lat":58,"lon":57},[61],{"name":62,"role":24,"phone":25,"phoneExt":20,"email":26},"Ahmad Masri, MD",{"type":48,"investigatorFullName":23,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Associate Professor",[66,69],{"name":67,"class":68},"Saint Lukes Hospital Mid America Heart Institute","UNKNOWN",{"name":70,"class":71},"Cytokinetics","INDUSTRY","100640080","phase-4-mavacamten-to-aficamten-transition-in-patients-with-obstructive-hypertrophic-cardiomyopathy-100640080",false,"NCT07600177","Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy","CMI-SWITCH","Inclusion Criteria:\n\n* Documented history of oHCM with documented resting and\u002For Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially.\n* Echo-derived LVEF ≥55% on mavacamten at the time of enrollment.\n* Patient willing to consent for the study and undergo the study procedures.\n\nExclusion Criteria:\n\n* Severe aortic stenosis or sub-aortic obstruction\n* Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis).\n* History of LVEF \\\u003C30%.\n* Paroxysmal atrial fibrillation (AF) with documented episode within 3 months.\n* Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation.\n* Documented history of current obstructive coronary artery disease (\\> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.","ALL","18 Years","90 Years",{"count":83,"type":84},40,"ESTIMATED","INTERVENTIONAL",[87],"PHASE4","This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).",[90],"Hypertrophic Cardiomyopathy (HCM)",[92,93,94,9],"aficamten","mavacamten","cardiac myosin inhibitor","2026-05-14",{"date":97,"type":98},"2026-05-20","ACTUAL",{"date":100,"type":98},"2026-05-05",{"date":102,"type":84},"2027-03-15",{"name":5,"class":6},2]